Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96JP9

UPID:
CDHR1_HUMAN

ALTERNATIVE NAMES:
Photoreceptor cadherin; Protocadherin-21

ALTERNATIVE UPACC:
Q96JP9; Q69YZ8; Q8IXY5

BACKGROUND:
Cadherin-related family member 1, identified by the alternative names Photoreceptor cadherin and Protocadherin-21, is speculated to be a calcium-dependent cell-adhesion molecule essential for photoreceptor cells' outer segment integrity, crucial for proper vision.

THERAPEUTIC SIGNIFICANCE:
Linked to Cone-rod dystrophy 15, a disease characterized by early severe vision loss due to rapid cone photoreceptor degeneration, Cadherin-related family member 1's function suggests its potential as a target for therapeutic intervention. Understanding its role could lead to breakthroughs in treating or managing this retinal dystrophy.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.